Sort

Search

01/08/2025 Hemodynamic support Prospective multicenter observational study of patients in shock treated with vasopressin: Protocol of the VASOPRESIN with vasopressin: VASOPRES Registry study protocol
Alvarez, RG, Ramasco, F, Alonso, JN, Mouriz, L, Rama, P, Bilbao, I, Carbonell, AP, Rodenas, MA, Ortega, F, Vives, M, Calvo, CA, Taboada, M, Azzam, A, Merino, M, Martinez, F, Dominguez, D, de Llano, CT, Adalia, R, Aguilar, G, Aldecoa, C, Mancha, B, Reyes, A, Giné, M, Prendes, D, Fernández, CG, de la Calle, I, Cendrero, M, López, AM, Herrero, JJ, de la Torre, I, Kattan, E, Hernández, G. Hemodynamic support Prospective multicenter observational study of patients in shock treated with vasopressin: Protocol of the VASOPRESIN with vasopressin: VASOPRES Registry study protocol. Revista Espanola De Anestesiologia Y Reanimacion. 2025; 72(7)DOI:10.1016/j.redar.2025.501768. PMID:. IF:(Q/D).
31/07/2025 A multiomics approach reveals novel regulators of plasma factor V levels, highlighting CLEC4M as a clearance receptor
Mohapatra, AK, Vlieg, AV, Kleber, ME, Martinez-Perez, A, Le, NQ, Hindberg, KD, Dusart, P, Germain, M, Thibord, F, Deleuze, JF, Delgado, GE, Goumidi, L, Suchon, P, Saut, N, Souto, JC, Butler, LM, Soria, JM, Hansen, JB, März, W, Rosendaal, FR, Castoldi, E, Peiretti, F, Sabater-Lleal, M, Trégouët, DA, Morange, PE. A multiomics approach reveals novel regulators of plasma factor V levels, highlighting CLEC4M as a clearance receptor. BLOOD. 2025; 146(5)DOI:10.1182/blood.2024027006. PMID:40359434. IF:23.100(Q1/1D).
31/07/2025 Unveiling the Spectrum: Clinical and Molecular Insights from a Spanish Pediatric Cohort with Hypermobility Disorders and Ehlers-Danlos Syndrome
Felipe, DF, Casas-Alba, D, Sadok, SH, Fernández, MT, Vega-Hanna, L, Plaza, L, Villa, AV, Armstrong, J, Guillén-Navarro, E, Martínez-Monseny, AF. Unveiling the Spectrum: Clinical and Molecular Insights from a Spanish Pediatric Cohort with Hypermobility Disorders and Ehlers-Danlos Syndrome. Genes. 2025; 16(8)DOI:10.3390/genes16080925. PMID:40869974. IF:2.800(Q2/5D).
25/07/2025 Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach
Zapatero, A, Alonso-Gordoa, T, Antolín, AR, Couñago, F, Sanmamed, N, Esteban, MD, Valcárcel, ML, Manneh, R, Borque-Fernando, A, González, NS, Maroto, P. Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach. Oncology Reviews. 2025; 19DOI:10.3389/or.2025.1599292. PMID:40787089. IF:(Q/D).